With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Injurious falls are common among people with chronic obstructive pulmonary disease (COPD) in the two years before de ...

A recent study conducted by researchers from Seattle-based University of Washington and Durham, N.C.-based Duke University found a strong association between the use of fall-risk increasing drugs and ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.